News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Oct 28, 2020

  European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options

  -- ARIKAYCE is the First and Only Therapy Approved in Both the European Union and United States for This Difficult-To-Treat Condition --
• Oct 20, 2020

  Insmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020
• Oct 2, 2020

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Sep 30, 2020

  Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day

  - Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned for 2021 -
• Sep 16, 2020

  Insmed to Host R&D Day on September 30, 2020
• Sep 9, 2020

  Insmed to Present at Three September Conferences
• Sep 7, 2020

  New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis

  --New Data from WILLOW Study also Presented During Late-Breaking Session at European Respiratory Society International Congress--
• Sep 4, 2020

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Aug 7, 2020

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Aug 6, 2020

  Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update

  --ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $42.5 Million for Second Quarter 2020--

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download